CBD, CBN and CBC Had Different Results in a Rat Jaw-Muscle Pain Model
A rat masseter-pain experiment summarized in an orofacial review found different effects across minor cannabinoids. Longer-lasting relief with a CBD–CBN combination did not establish that every cannabinoid or mixture worked alike.
The model tested induced muscle sensitivity
Wong and colleagues used nerve-growth-factor-induced masseter sensitization in rats. The review describes local cannabinoid conditions, including CBD, CBN, CBC and CBD–CBN combinations. This is a model of experimentally heightened muscle sensitivity, with behavioral responses used to assess its reduction. It is not a clinical trial in people with temporomandibular disorders or fibromyalgia.
The compounds did not produce one class-wide result
The review reports reversal of mechanical sensitization with the higher CBD concentration and with CBD–CBN combinations. CBC alone was ineffective under the reported conditions. It also describes longer-lasting analgesic effects from combining CBD and CBN than from either compound alone. Duration is a distinct feature of a response; it should not be silently converted into proof of a larger peak benefit or formal pharmacological synergy.
Local concentration is part of the evidence
The table expresses several conditions in milligrams per milliliter. That describes preparation concentration in this local experiment, rather than a blood concentration or an oral human dose. The review reports no motor impairment in the tested conditions, which remains narrower than comprehensive neurological or driving safety. The useful conclusion is that compound identity and combination composition mattered in this particular rat model. Human efficacy, an optimal formulation and the consequences of prolonged use require separate evidence; a generic label such as minor cannabinoids loses these distinctions.
Related analysis: the broader findings and limitations of this research.
Research cited
The study observations discussed here are reported in the supplied review: Walczyńska-Dragon and colleagues (2025). Cannabidiol for Orofacial and Upper-Quarter Pain: A Systematic Evaluation of Therapeutic Potential. Journal of Clinical Medicine.
